Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040687 · ClinicalTrials.gov registry record · Phase 1
Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
A Phase 1 study of Healthy Volunteer, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03040687 is a Phase 1 study of Healthy Volunteer that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 60 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03040687, a Phase 1 study of Healthy Volunteer, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea worldwide. Vaccines and therapeutics are under development to prevent ETEC disease in children and travelers. One approach is to use passive protection (antibodies) to prevent infection. The purpose of this study are to assess the safety of serum-derived bovine immunoglobulins in healthy adult subjects when orally administered and to estimate protective efficacy of those preparations against moderate-severe diarrhea upon challenge with the ETEC strain B7A.
Conditions Studied
Interventions
- BIOLOGICAL Anti CS6 BSIgG product (Lot PD1601105CS)
- BIOLOGICAL Anti B7A BSIgG product (Lot PD1601132ET)
- BIOLOGICAL Bovine Immunoglobin Negative Control (Lot PD161071NC)
- BIOLOGICAL B7A- CS6-expressing ETEC challenge strain
Study Locations (1)
Maryland
- Johns Hopkins Center for Immunization Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040687
The ClinicalTrials.gov registry entry for NCT03040687 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (70% lower). The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 4 interventions - of which Anti CS6 BSIgG product (Lot PD1601105CS) is the first listed.
NCT03040687 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03040687 about?
NCT03040687 is a clinical study titled "Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge". Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea worldwide. Vaccines and therapeutics are under development to prevent ETEC disease in children and travelers. One approach is to use passive protection (antibodies) to prevent infection. The purpose of this study are to assess the ...
What is the current status of trial NCT03040687?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-01. Estimated completion is 2017-08.
What conditions does trial NCT03040687 study?
This clinical trial studies the following conditions: Healthy Volunteer.
What interventions are being tested in trial NCT03040687?
The interventions under investigation include: Anti CS6 BSIgG product (Lot PD1601105CS) (BIOLOGICAL), Anti B7A BSIgG product (Lot PD1601132ET) (BIOLOGICAL), Bovine Immunoglobin Negative Control (Lot PD161071NC) (BIOLOGICAL), B7A- CS6-expressing ETEC challenge strain (BIOLOGICAL).
Who is sponsoring clinical trial NCT03040687?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03040687 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.